Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia.

ABSTRACT:

Objectives

There is growing evidence that antihypertensive agents, particularly centrally acting ACE inhibitors (CACE-Is), which cross the blood-brain barrier, are associated with a reduced rate of cognitive decline. Given this, we compared the rates of cognitive decline in clinic patients with dementia receiving CACE-Is (CACE-I) with those not currently treated with CACE-Is (NoCACE-I), and with those who started CACE-Is, during their first 6 months of treatment (NewCACE-I).

Design

Observational case-control study.

Setting

2 university hospital memory clinics.

Participants

817 patients diagnosed with Alzheimer's disease, vascular or mixed dementia. Of these, 361 with valid cognitive scores were included for analysis, 85 CACE-I and 276 NoCACE-I.

Measurements<

SUBMITTER: Gao Y 

PROVIDER: S-EPMC3703568 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature